MHRA launches call for evidence on AI regulation in UK healthcare sector
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has launched a call for evidence seeking input from the healthcare…
All articles by Salong Debbarma
Salong Debbarma
-
-
J&J receives FDA approval for lung cancer therapy
Johnson & Johnson (J&J) has received the US Food and Drug Administration (FDA) approval for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj),…
-
Formycon and Zydus sign exclusive agreement for FYB206 supply
Formycon and Zydus Lifesciences have entered an exclusive licensing and supply agreement for FYB206, a biosimilar of MSD’s Keytruda (Pembrolizumab),…
-
Health Canada approves Biogen’s Zurzuvae for PPD treatment
Biogen has received a notice of compliance (NOC) from Health Canada for Zurzuvae (zuranolone), a neuroactive steroid (NAS), as a treatment…
-
EC approves Roche’s Gazyva to treat active lupus nephritis
Roche has received approval from the European Commission (EC) for its humanised monoclonal antibody Gazyva/Gazyvaro (obinutuzumab) along with mycophenolate mofetil…
-
Inductive Bio gains $21m ARPA-H funds for drug prediction models
New York City-based tech company Inductive Bio has secured up to $21m from the US Advanced Research Projects Agency for…
-
Viatris signs agreements with Biocon on $815m stake sale
Viatris has signed definitive agreements for the sale of its equity stake in Biocon Biologics to Biocon for $815m. Viatris…
-
Denali makes $275m funding agreement with Royalty Pharma
Denali has entered a $275m royalty funding agreement with Royalty Pharma based on future net sales of tividenofusp alfa therapy.…
-
Takeda and Innovent fulfil close conditions for ADC and IO therapies
Takeda and Innovent have closed their global partnership for next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, following the fulfilment…
-
Formosa and Rxilient sign licensing agreement for APP13007
Formosa Pharmaceuticals and Rxilient Medical have signed an exclusive licensing agreement for the commercialisation of Byqlovi, clobetasol propionate ophthalmic suspension,…